一分钟看懂
这是一项关于结直肠癌的II 期研究，登记的药物或干预包括FMT+QL1706+Bevacizumab+XELOX，当前状态为招募中。登记地点显示中国常州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
FMT+QL1706+Bevacizumab+XELOX · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Second People's Hospital of Changzhou · 常州
公开的入选条件
- 1. Histological or cytological confirmed advanced colorectal cancer with liver metastasis.
- 2. Signed written informed consent.
- 3. Have not received anti-tumor treatment.
- 4. According to the investigators assessment, at least one measurable target lesion defined by RECIST v1.1.
- 5. Patients of both sexes, aged ≥18 years and ≤75 years.
- 6. ECOG PS 0-1;
- 7. Expected survival time ≥ 3 months;
- 8. Have adequate organ and bone marrow function, laboratory examination within 7 days prior to enrollment meets the following requirements, as follows:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06801665；登记信息更新于 2026-09-10。